BioAge Labs

BIOA

Market cap $728M

BioAge shares catapulted Monday on promising results for the company's cardiovascular diseases treatment, which could eventually rival Eli Lilly.

First BGE-102 MAD cohort completed in obese individuals with elevated hsCRP receiving 120 mg QD; demonstrated rapid and profound reduction in inflammatory markers

BioAge Labs' leading candidate is far too early in the process to make reliable predictions. The biotech will encounter plenty of challengers in its chosen therapeutic area.

BGE-102 was well-tolerated in SAD and initial MAD cohorts, with a pharmacokinetic profile supporting once-daily oral dosing Strong target engagement: BGE-102 achieved 90-98% suppression of IL-1β, a cytokine directly downstream of NLRP3, at Day 14 High brain penetration: BGE-102 doses of 60 mg and higher exceeded target IC90 levels in cerebrospinal fluid (CSF) at Day 14 Company is expanding the Phase 1 trial to include MAD cohorts in participants with obesity and elevated hsCRP, with data anticipated in first half of 2026 EMERYVILLE, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) ("BioAge"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced positive interim data from the ongoing Phase 1 single ascending dose (SAD) / multiple ascending dose (MAD) clinical trial evaluating BGE-102, a potent, structurally novel, orally available, brain-penetrant small molecule NLRP3 inhibitor being developed for treatment of patients with cardiovascular risk factors.

EMERYVILLE, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will present at the Piper Sandler 37th Annual Healthcare Conference taking place in New York, NY on December 2-4, 2025.

EMERYVILLE, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will present at the Jefferies Global Healthcare Conference in London, November 17–20, 2025.

The weight-loss drug market is already enormous, but could nearly double in size by 2035. BioAge Labs is still years away from revenue and even more years away from actual profits.

BioAge Labs is developing a promising weight management candidate. The medicine could have several advantages over approved anti-obesity drugs.

BioAge Labs' stock recently jumped, and a Wall Street analyst thinks it has further to climb. The company is focusing on a source of inflammation in the brain as a way to regulate appetites.

The BioAge lawsuit alleges investors were misled on lead drug azelaprag's safety; trial halt over liver concerns caused shares to fall 77% in one day.